Skip to main content

Table 2 Baseline demographic and clinical characteristics

From: Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study

 

All subjects

Group 1

30 mg edoxaban plus 2.5 mg prasugrel

Group 2

30 mg edoxaban plus 3.75 mg prasugrel

n = 24

n = 12

n = 12

Age (years)

 Mean (SD)

72 (4)

71 (4)

73 (3)

 65 to < 75, n (%)

16 (66.7)

9 (75.0)

7 (58.3)

 75 to 80, n (%)

8 (33.3)

3 (25.0)

5 (41.7)

Height (cm)

 Mean (SD)

164.0 (5.7)

162.5 (5.7)

165.5 (5.6)

Weight (kg)

 Mean (SD)

56.4 (2.2)

55.8 (2.4)

57.0 (1.9)

 > 50 to 60, n (%)

24 (100.0)

12 (100.0)

12 (100.0)

BMI (kg/m2)

 Mean (SD)

21.1 (1.6)

21.3 (1.6)

21.0 (1.6)

eGFR (mL/min/1.73m2)

 Mean (SD)

73.5 (7.0)

75.5 (6.6)

71.6 (7.1)

 60 to < 90, n (%)

24 (100.0)

12 (100.0)

12 (100.0)

CLcr(mL/min)

 Mean (SD)

67.2 (7.2)

68.7 (6.1)

65.8 (8.1)

 ≥50, n (%)

24 (100.0)

12 (100.0)

12 (100.0)

Medical historya

 No, n (%)

10 (41.7)

5 (41.7)

5 (41.7)

 Yes, n (%)

14 (58.3)

7 (58.3)

7 (58.3)

  1. SD standard deviation, IQR interquartile range, BMI body mass index, CLcr creatinine clearance
  2. aAppendicitis, polyps in the colon, hemorrhoids, cataract, hepatitis A, tuberculosis, and inguinal hernia